ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OCGN vs LCTX // DIVIDEND YIELD & FCF PAYOUT SAFETY

Ocugen Inc. (NASDAQ) VS. Lineage Cell Therapeutics Inc. (NYSE) • 15-METRIC TALLY: OCGN 0 — LCTX 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCGN VS. LCTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OCGN LCTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -22.65% -7.46% -15.19 LCTX /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 8.80% 53.20% -44.40 LCTX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 28.3 50.8 -22.53 LCTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $252.4M $260.5M -$8.1M LCTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OCGN REV LCTX REV OCGN GROSS % LCTX GROSS % OCGN FCF LCTX FCF
FY 2025 $4.4M $14.6M — — -$57.1M -$19.4M
FY 2024 $4.1M $9.5M — 96.5% -$45.5M -$23.7M
FY 2023 $6.0M $8.9M — — -$62.1M -$28.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCGN // BETA —
LCTX // BETA —